Lymphoma

Data presented at 2017 ASH showed that mogamulizumab resulted in improved progression free survival (PFS), overall response rates (ORR), and better quality of life in patients with previously treated CTCL compared with vorinostat.

Patients with Hodgkin lymphoma treated with a drug combination including brentuximab vedotin achieved superior progression-free survival, with a reduction in the risk for progression, death, or need for additional anticancer therapy, compared with the standard four-drug chemotherapy regimen.

In this interview, we discuss the biology and the therapeutic strategies for primary mediastinal B-cell lymphoma.

A long-term analysis of the FOLL05 trial found favorable outcomes at 8 years in advanced-stage follicular lymphoma patients treated with three different rituximab/chemotherapy combinations.

Use of two BEACOPP regimens that incorporated brentuximab resulted in improved rates of complete response and complete remission at the end of treatment.

Integrating genetic risk factors with minimal residual disease improves the accuracy of risk stratification for children with acute lymphoblastic leukemia.

Two-year survivors with relapsed Hodgkin lymphoma or diffuse large B-cell lymphoma after transplant had an excess late mortality risk vs the general population.

Novartis has submitted an application to the FDA to extend the indications for its CAR T-cell therapy tisagenlecleucel (Kymriah) for its use in adult patients with relapsed or refractory diffuse large B-cell lymphoma who are not eligible for autologous stem cell transplant.

The FDA has granted accelerated approval to acalabrutinib (Calquence) for the treatment of mantle cell lymphoma in adult patients who have received at least one previous therapy.

The number of extranodal sites of disease did not influence outcomes among young patients with high-risk DLBCL treated with rituximab-dose-dense chemotherapy with or without high-dose chemotherapy and autologous stem-cell transplantation.

Elderly patients, including those treated with an R-CHOP regimen, tend to have poor outcomes regardless of salvage therapy.

The pharmaceutical company AstraZeneca retracted a paper and acknowledged that some preclinical data were falsified regarding its developmental agent acalabrutinib, which is under investigation for use in a number of malignancies.

The FDA has approved the CAR T-cell therapy axicabtagene ciloleucel (Yescarta) for the treatment of large B-cell lymphomas in adults who have failed or relapsed after two or more prior treatments.

A new study found that Hodgkin lymphoma patients treated with consolidative proton therapy after chemotherapy had “excellent” early relapse-free survival rates and no early grade 3 radiation-related toxicities.

In this interview with Jorge Cortes, MD, he discusses why gemtuzumab ozogamicin is experiencing a comeback for the treatment of patients with acute myeloid leukemia.

There is a high economic burden associated with the treatment of relapsed or refractory Hodgkin lymphoma. A recent study found that patients undergoing treatment for the disease incurred a median total all-cause cost of about $300,000.

Treatment with obinutuzumab along with chemotherapy resulted in longer progression-free survival than rituximab and chemotherapy in patients with previously untreated advanced-stage follicular lymphoma, according to a large randomized trial.

Maintenance therapy with rituximab following autologous stem cell transplantation prolonged progression-free, event-free, and overall survival compared with observation in patients with mantle cell lymphoma, according to a new study.

A new study identified simple risk factors that could help identify patients with extranodal marginal zone lymphoma of the mucosa-associated lymphoid tissue (MALT lymphoma) at high risk for poor outcomes.

The FDA has approved the novel PI3K inhibitor copanlisib (Aliqopa) for the treatment of relapsed follicular lymphoma in adult patients who have received at least two prior systemic therapies.

The US Food and Drug Administration has granted Priority Review to obinutuzumab in combination with chemotherapy and followed by obinutuzumab alone for treatment-naïve follicular lymphoma.

Adding obinutuzumab to cyclophosphamide, doxorubicin, vincristine, and prednisone (G-CHOP) failed to improve progression-free survival compared with rituximab plus CHOP in patients with previously untreated diffuse large B-cell lymphoma.

In this interview we discuss the link between breast implants and anaplastic large-cell lymphoma, a rare type of T-cell lymphoma.

Pediatric patients with ALK-positive anaplastic large cell lymphomas and inflammatory myofibroblastic tumors had strong responses to treatment with crizotinib.

The FDA has approved inotuzumab ozogamicin (Besponsa) for the treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia.